A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks
Latest Information Update: 21 Apr 2014
At a glance
- Drugs NAB 001 (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Promius Pharma
Most Recent Events
- 21 Apr 2014 New trial record